MNPR: monopartx.com Amount of Cash per Share

Corporate emblem and logo of Monopar Therapeutics (MNPR)

Monopar Therapeutics focuses on developing low-toxicity treatments for severe tumors, which contrasts with its long-term status as a reputable developer of targeted therapy. Cash per share currently reflects this balance, where 19.13 determines the current value of the metric. R&D efficiency is maintained by outsourcing early-stage research to external contract organizations.

MNPR: Monopar Therapeutics Inc Cash per Share 07/04/2022 - 11/20/2026

Analytical breakdowns for Monopar Therapeutics

- market price and analyst price targets:
- cash position and cash flow details:
Summary company analysis:MNPR, Monopar Corp
Original product of monopartx.com

For Monopar Therapeutics (MNPR), whose resilience relies on patent protection for R&D developments and FDA approval, cash per share currently serves as an indicator of financial survival. This ratio, determined by dividing liquid capital by the number of shares, demonstrates a margin of safety against bankruptcy, although stagnation of this value signals the inflationary depreciation of the company's unused resources.